Lipocine (STU:2VT0) Accumulated Depreciation: €-1.14 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2VT0 Lipocine Inc STU:2VT0
49 GF Score
Price €3.94
GF Value €2.44
! 4 Warning Signs
View Full Analysis

What is Lipocine Accumulated Depreciation?

Lipocine STU:2VT0 49 Accumulated Depreciation is €-1.14 Mil as of Jun. 2026. GuruFocus rates STU:2VT0 with a GF Score™ of 49/100 and a GF Value™ of €2.44. The stock has 4 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Lipocine's quarterly accumulated depreciation increased from Dec. 2025 (€-1.10 Mil) to Mar. 2026 (€-1.12 Mil) and increased from Mar. 2026 (€-1.12 Mil) to Jun. 2026 (€-1.14 Mil).

Lipocine's annual accumulated depreciation increased from Dec. 2023 (€-1.08 Mil) to Dec. 2024 (€-1.17 Mil) but then stayed the same from Dec. 2024 (€-1.17 Mil) to Dec. 2025 (€-1.10 Mil).

Lipocine Accumulated Depreciation Related Terms

Lipocine Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Lipocine's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipocine Accumulated Depreciation Chart

Lipocine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.01 -1.09 -1.08 -1.17 -1.10

Lipocine Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.09 -1.08 -1.10 -1.12 -1.14
STU:2VT0
49GF Score
Lipocine Inc STU:2VT0
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lipocine Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of €-1.14 Mil mean?
Lipocine (STU:2VT0) has a Accumulated Depreciation of €-1.14 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Lipocine and its competitors.
Is Lipocine's Accumulated Depreciation too high?
Lipocine's current Accumulated Depreciation is €-1.14 Mil. Overall, Lipocine has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Lipocine's Accumulated Depreciation compare to TPST and CYCN?
Lipocine's Accumulated Depreciation of €-1.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Lipocine and its competitors. Lipocine's current Accumulated Depreciation is €-1.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Lipocine (STU:2VT0) has a current Accumulated Depreciation of €-1.14 Mil. The stock's GF Value™ is €2.44, compared to a current price of €3.94 — trading 61.6% above its estimated fair value. The current Accumulated Depreciation is €-1.14 Mil. Lipocine's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Lipocine (STU:2VT0), the current Accumulated Depreciation is €-1.14 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lipocine (STU:2VT0) Overvalued in 2026?

Based on GuruFocus' analysis, Lipocine stock appears to be overvalued. The current stock price of €3.94 is trading 61.6% above its estimated GF Value™ of €2.44.

Key valuation signals for STU:2VT0:

  • Accumulated Depreciation: €-1.14 Mil
  • GF Value™: €2.44 vs. price of €3.94 (61.6% above fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the STU:2VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lipocine Business Description

Other Exchanges LPCN:USA
Address 675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
49GF Score

Get the complete analysis for STU:2VT0

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.94
Price
€2.44
GF Value